Endocrinology, Vol 133, 1978-1982, Copyright © 1993 by Endocrine Society

ARTICLES

Abnormalities in osteoclast precursors and marrow accessory cells in Paget's disease

A Demulder, S Takahashi, FR Singer, DJ Hosking and GD Roodman
Veterans Administration Medical Center, San Antonio, Texas 78284.

Paget's disease of bone is characterized by increased numbers of abnormal osteoclasts. To determine if osteoclast precursors were increased or abnormal in this disease, we examined CFU-GM, the committed granulocyte-macrophage progenitor and the most likely precursor for osteoclasts. In cultures of unfractionated marrow mononuclear cells, CFU-GM colony formation was significantly increased in Paget's marrow cultures compared to that in normal cells (356 +/- 44 vs. 271 +/- 15/10(5) cells; P < 0.05). However, when we enriched hematopoietic precursors from Paget's and normal marrow samples using an antibody that recognizes the CD34 antigen present on most hematopoietic precursors, we found that similar numbers of CFU-GM colonies were formed (87 +/- 13/10(4) cells plated vs. 83 +/- 13). Coculture experiments with highly purified hematopoietic precursors (CD34+ cells) and nonhematopoietic marrow accessory cells (CD34- cells) revealed that the growth of Paget's precursors was significantly enhanced above expected levels by normal or Pagetic CD34- cells (P < 0.05). CFU-GM colony formation was also significantly enhanced when normal CD34+ cells were cocultured with Pagetic, but not with normal, CD34- cells. In addition, CFU-GM colony-derived cells from Paget's patients were hyperresponsive to 1,25-dihydroxyvitamin D3 and could form osteoclast-like multinucleated cells with 1,25-dihydroxyvitamin D3 concentrations one tenth of that required for normal multinucleated formation (10(-11) vs. 10(-10) M). These data suggest that osteoclast precursors may be abnormal in Paget's disease, and other cells in the Pagetic marrow microenvironment may further enhance the growth and differentiation of these abnormal precursors.

This article has been cited by other articles:

				R. Feng, G. Anderson, G. Xiao, G. Elliott, L. Leoni, M. Y. Mapara, G. D. Roodman, and S. Lentzsch SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-{kappa}B activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth Blood, March 1, 2007; 109(5): 2130 - 2138. [Abstract] [Full Text] [PDF]

				G. R. Klein and J. Parvizi Surgical Manifestations of Paget's Disease. J. Am. Acad. Ortho. Surg., October 1, 2006; 14(10): 577 - 586. [Abstract] [Full Text] [PDF]

				G. Anderson, M. Gries, N. Kurihara, T. Honjo, J. Anderson, V. Donnenberg, A. Donnenberg, I. Ghobrial, M. Y. Mapara, D. Stirling, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1 Blood, April 15, 2006; 107(8): 3098 - 3105. [Abstract] [Full Text] [PDF]

				A. A. Ragab, J. L. Nalepka, Y. Bi, and E. M. Greenfield Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells Am J Physiol Cell Physiol, September 1, 2002; 283(3): C679 - C687. [Abstract] [Full Text] [PDF]

				S. Y. Rha, E. Izbicka, R. Lawrence, K. Davidson, D. Sun, M. P. Moyer, G. D. Roodman, L. Hurley, and D. Von Hoff Effect of Telomere and Telomerase Interactive Agents on Human Tumor and Normal Cell Lines Clin. Cancer Res., March 1, 2000; 6(3): 987 - 993. [Abstract] [Full Text]

				K. Ziambaras, W. A. Totty, S. L. Teitelbaum, M. Dierkes, and M. P. Whyte Extraskeletal Osteoclastomas Responsive to Dexamethasone Treatment in Paget Bone Disease J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3826 - 3834. [Abstract] [Full Text] [PDF]

				N. A. ATHANASOU Current Concepts Review - Cellular Biology of Bone-Resorbing Cells J. Bone Joint Surg. Am., July 1, 1996; 78(7): 1096 - 1112. [Full Text]